Jun Feng

Title: Innovations of Jun Feng in Immunotherapy

Introduction

Jun Feng is an accomplished inventor based in Los Angeles, CA. He has made significant contributions to the field of immunotherapy, particularly through his innovative work on chimeric receptors. His research focuses on the DLL3 antigen, which plays a crucial role in cancer treatment.

Latest Patents

Jun Feng holds a patent for "Chimeric receptors to DLL3 and methods of use thereof." This patent includes antigen binding molecules, chimeric receptors, and engineered immune cells targeting DLL3. The invention also encompasses vectors, compositions, and methods for treatment and detection using these DLL3 antigen binding molecules and engineered immune cells. He has 1 patent to his name.

Career Highlights

Feng is currently employed at Amgen Inc., a leading biotechnology company known for its innovative therapies. His work at Amgen has allowed him to further develop his ideas and contribute to groundbreaking advancements in the field of cancer treatment.

Collaborations

Some of his notable coworkers include Michael John Giffin and Melissa Thomas. Their collaborative efforts have enhanced the research and development of new therapeutic strategies.

Conclusion

Jun Feng's contributions to immunotherapy through his patent on DLL3 chimeric receptors exemplify the innovative spirit of modern science. His work continues to pave the way for advancements in cancer treatment and detection.